threonate
Small moleculeexperimental
Magnesium L-Threonate (MgT) is the most appropriate Mg salt that strengthens the cholinergic system and improves brain-related functions. It is used to improve memory, assist with sleep, and to enhance overall cognitive function. Mg, an intracellular cofactor for many enzymes, is a modulator of the N-methyl-D-aspartate (NMDA) receptor that is involved in memory function and depression. Experiments on rodents have shown that oral magnesium-L-Threonate also prevents neuropathic pain induced by chemotherapy. — NCATS
Clinical trial activity
9 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
2
Earliest trial started Aug 1, 2012 (NCT02363634)
Timeline
Indications
Approved for
Mechanism of action
- Unspecified targetUnclear
Unclear
Chemistry & pharmacology
Loading structure…
SMILES
[Mg++].OC[C@H](O)[C@@H](O)C([O-])=O.OC[C@H](O)[C@@H](O)C([O-])=O- Mol. weight
- 294.4958 g/mol
Oral
No
Parenteral
No
Topical
No
Sources
- NCATS1Y26ZZ0OTM ↗
Also known as
- 2,3,4-trihydroxy-(threo)-butanoic acid
- calcium l-threonate
- calcium threonate
- calcium threonate
- calcium threonate
- clarimem
- l-tams compound
- l-threonic acid magnesium salt
- l-threonic acid magnesium salt
- l-threonic acid magnesium salt
- magnesium l-threonate
- magnesium l-threonate
- magnesium threonate
- magnesium threonate
- magnesium threonate
- mmfs-01
- mmfs-202-302
- threonate
- threonic acid
- threonic acid, dl-
- threonic acid, l-
- threonic acid, (r*,r*)-isomer
- threonic acid, (r-(r*,s*))-isomer
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06959745 | N/A | May 15, 2025 | Shantou University |
| NCT06902285 | Phase 4 | Apr 21, 2025 | University of Miami |
| NCT06889584 | N/A | Feb 15, 2025 | University of South Carolina |
| NCT03531684 | Phase 2 | Mar 20, 2018 | Neurocentria, Inc., Ohio State University |
| NCT02558790 | Phase 2 | Mar 1, 2016 | Harvard University, Neurocentria, Inc. |
| NCT02496676 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2015 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT02237235 | Phase 4 | Aug 1, 2014 | Brain & Behavior Research Foundation, Neurocentria, Inc., Northwestern University |
| NCT02210286 | N/A | Jul 1, 2014 | Magceutics, Inc., Stanford University |
| NCT02363634 | N/A | Aug 1, 2012 | MRA Clinical Research |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Neurocentria, Inc. | For profit | 3 | 1 | 2 | 2014 |
| Brain & Behavior Research Foundation | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Magceutics, Inc. | For profit | 1 | 0 | 1 | 2014 |
| MRA Clinical Research | Academic/Hospital | 1 | 1 | 1 | 2012 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2015 |
| Northwestern University | Academic/Hospital | 1 | 1 | 1 | 2014 |
| Ohio State University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Shantou University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Stanford University | Academic/Hospital | 1 | 1 | 1 | 2014 |
| University of Miami | Academic/Hospital | 1 | 1 | 1 | 2025 |
| University of South Carolina | Academic/Hospital | 1 | 1 | 1 | 2025 |
12 organizations
Page 1 / 1